NEW YORK - Immunocore kwuru na Mọnde ọ ga-ere 3,733,333 mbak na ntinye ego ego nke onwe (PIPE) nke a na-atụ anya ịkwalite $ 140 nde.
N'okpuru nkwekọrịta ahụ, Immunocore ga-ere ngwaahịa ya na ndị na-adịghị eme ntuli aka maka $ 37.50 kwa òkè. Ndị na-etinye ego nke ụlọ ọrụ ahụ na-etinye aka na ego ahụ gụnyere RTW Investments, Rock Springs Capital na General Atlantic. A na-atụ anya na nkwekọrịta PIPE ga-agwụ na July 20.
Companylọ ọrụ ahụ ga-eji ego enwetara ego ya na ndị na-achọ ọkpọkọ ọrịa na-efe efe, gụnyere mmepe nke onye ndoro-ndoro ochichi oncology, Kimmtrak (tebentafusp-tebn), iji gwọọ HLA-A * 02: 01 ezigbo akpụkpọ anụ na uveal melanoma. A na-atụ anya na ego, yana ego sitere na Kimmtrak, ga-akwado ọrụ Immunocore 2025.
N'afọ a, a kwadoro Kimmtrak maka ndị na-arịa ọrịa HLA-A * 02: 01 na-adịghị mma ma ọ bụ metastatic uveal melanoma na US, Europe na UK, n'etiti mba ndị ọzọ.
Immunocore na-emepekwa ndị na-eme nchọpụta oncology anọ ọzọ, gụnyere ọgwụ abụọ ọzọ T-cell receptor drugs na Phase I / II tests na elu siri ike etuto. Otu n'ime ọgwụ ndị a na-emepụta maka HLA-A * 02: 01-positive na MAGE-A4-positive ọrịa, na ndị ọzọ lekwasịrị HLA-A * 02:01 na PRAME-eme ntuli aka-positive ụlọ ọrụ na-enwekwa abụọ mmepe etuto ahụ.
Amụma nzuzo. Usoro na ọnọdụ.Copyright © 2022 GenomeWeb, ngalaba azụmahịa nke Crain Communications. echekwabara ikike niile.
Oge nzipu: Jul-30-2022